Bio-Rad Laboratoriesvs.Natera
BIO vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 5.8× larger than Bio-Rad Laboratories by market cap; year to date, Natera leads (+72.7% vs +21.4%).
Side by side
| BIO | NTRA | |
|---|---|---|
| Market cap | $9.6B | $55.6B |
| Price | $360.40 | $390.79 |
| Today | −2.0% | −1.2% |
| Return YTD | +21.4% | +72.7% |
| Return 1Y | +24.1% | +134.7% |
| Since June 26, 2026 | +19.8% | +49.2% |
| P/E | 43.0 | — |
| P/S | 3.7 | 20.5 |
| P/B | 1.3 | 30.5 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More BIO & NTRA comparisons
Other head-to-heads in the Diagnostics segment.